BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ICU Medical, Inc. (ICUI)'s ChemoClave(TM) System Included in Mobius Theraputics™' Mitosol(R) Kit for Use in Glaucoma Surgery


6/8/2012 10:22:44 AM

SAN CLEMENTE, Calif. and ST. LOUIS, June 7, 2012 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI) and Mobius Therapeutics, LLC today jointly announced that ICU Medical's ChemoClave system for the safe handling of hazardous drugs will be packaged with Mobius Therapeutics' Mitosol® kit, an FDA-cleared drug used in ophthalmic surgery containing the active ingredient Mitomycin-C, which is cytotoxic and listed on NIOSH Hazardous Drug List. By incorporating ChemoClave components into the kit, clinicians will be able to reconstitute Mitosol on the surgical field, improving shelf life and consistency of the delivered drug, without changing current surgical technique. Both the ChemoClave system and the Mitosol kit can be seen at the upcoming American Society of Health System Pharmacists (ASHP) Summer meeting in Baltimore, MDJune 10-12, 2012.

"Although the use of mitomycin in eye surgery has been well established by medical literature, the compound is highly unstable and can present a hazard to doctors and nurses in the operating room when preparing the drug," explained Mobius Therapeutics President Ed Timm. "By incorporating the ChemoClave system into the Mitosol kit, we can minimize potential hazards for clinicians in the operating room and provide patients with a product that is consistent, assuredly sterile, and assuredly potent since it is mixed using the completely closed, sterile ChemoClave system."

More information about ChemoClave can be found at www.icumed.com, while full prescribing information for Mitosol can be found www.mobiustherapeutics.com.

Media Contact:Tom McCall
Vice President, Marketing
949-291-8959
tmccall@icumed.com

About ICU Medical, Inc.: ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. ICU Medical's products improve patient outcomes by helping prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company's complete product line includes custom I.V. systems, closed delivery systems for hazardous drugs, needle-free I.V. connectors, catheters and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California. For more information, visit www.icumed.com.

About Mobius Therapeutics, LLC: Mobius Therapeutics is an early stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the refractive and corneal indications are awaiting approval by the Food and Drug Administration.

SOURCE ICU Medical, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES